Q-omics provides the consensus-scored CST2 profile across patient tissues and cancer cell-line models. CST2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CST2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CST2 RNA expression shows 15,083 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, COAD, and BRCA as cancer lineages where CST2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CST2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CST2 survival associations across molecular data types. CST2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CST2 RNA expression–survival associations across cancer types. High CST2 expression shows unfavorable associations in KIRP, KIRC, SKCM, OV and GBM, but favorable associations in BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CST2 RNA expression.
This table summarizes CST2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CST2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CST2 shows higher tumor expression in COAD, THCA, STAD, BLCA, KIRC and KIRP. The COAD box plot shows higher CST2 RNA expression in tumor versus normal tissue (log2 FC = +3.282, t-test p < 0.001).
This table shows molecular features associated with CST2 in patient tissues and cancer cell lines. In patient samples, CST2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CST2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
